Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MB | P02144 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11121919 | 0.81 | PTPN11 (0.47) | KMT2AMEN1 | |
| SCHEMBL973371 | 0.80 | KMT2A (0.55) | TDP1SMN1; SMN2L3MBTL1HTTKMT2A | |
| SCHEMBL10344720 | 0.79 | TSHR (0.53) | CA12CA1CA2TSHRCA9 | |
| SCHEMBL3064656 | 0.78 | SMN1; SMN2 (0.50) | TDP1SMN1; SMN2L3MBTL1HTTKMT2A | |
| SCHEMBL95120 | 0.78 | SMN1; SMN2 (0.50) | TDP1SMN1; SMN2L3MBTL1HTTKMT2A | |
| SCHEMBL2683899 | 0.78 | SMN1; SMN2 (0.50) | TDP1SMN1; SMN2L3MBTL1HTTKMT2A | |
| SCHEMBL97146 | 0.76 | SMN1; SMN2 (0.52) | TDP1SMN1; SMN2L3MBTL1HTTKMT2A | |
| SCHEMBL861674 | 0.75 | SMN1; SMN2 (0.84) | TDP1SMN1; SMN2L3MBTL1HTTKMT2A | |
| SCHEMBL6592103 | 0.74 | CA1 (0.46) | TDP1SMN1; SMN2L3MBTL1HTTKMT2A | |
| SCHEMBL11125734 | 0.74 | MEN1 (0.35) | TDP1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556914-B2 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | ABBVIE INC. (US) | 2020-02-11 | — | — | US | claimed |
| EP-3350187-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2017046117-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | ABBVIE INC. (US) | 2017-03-23 | — | — | WO | claimed |
| US-20170073353-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-16 | — | — | US | claimed |
| EP-1053224-B1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2002-08-21 | — | — | EP | claimed |
| US-6369069-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | claimed |
| US-10556914-B2 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | ABBVIE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3350187-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046117-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | ABBVIE INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170073353-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-2393552-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090299-A1 | A NOVEL CYANOPYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999032448-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999028303-A1 | PROCESS OF PREPARING SUBSTITUTED PYRIMIDINONES | AMGEN, INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0028351-B1 | REACTIVE DYESTUFFS AND THEIR USE IN DYEING MATERIALS CONTAINING OH OR NH | BAYER AG (DE) | 1984-02-22 | — | — | EP | disclosed |
| EP-0028351-A2 | Reactive dyestuffs and their use in dyeing materials containing OH or NH | BAYER AG (DE) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556914-B2 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | GABRB1, GABBR1, GABBR2 | TDP1 2334/4885SMN1; SMN2 2210/4885L3MBTL1 4293/4885 |
| US-20170073353-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | GABRB1, GABBR1, GABBR2 | TDP1 2334/4885SMN1; SMN2 2210/4885L3MBTL1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.